Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types
- Dr. Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory Board
- Dr. Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane Durant des Aulnois appointed as Chief Financial Officer
- Accelerating development of first-in-class ADCs in multiple large solid tumor types designed against novel targets with a focus on eliminating hard-to-treat resistant cancer cells
Barcelona, Spain, 19 February 2025: Ona Therapeutics (“Ona”), a global biotech company pioneering first-in-class antibody-drug conjugates (ADCs), today announced key leadership appointments to support its rapid growth and pipeline advancement. Dr. Aleix Prat, a global leader in drug and biomarker development, has been appointed Chair of the Advisory Board. Additionally, Dr. Jutta Amersdorffer has joined as Chief Medical Officer and Stéphane Durant des Aulnois as Chief Financial Officer. These appointments come at a pivotal time as Ona accelerates the development of its first-in-class ADC therapeutics, targeting novel tumor-specific markers to eliminate hard-to-treat, resistant cancer cells and advance its pipeline toward clinical development across multiple cancer types.
